Leonardo Gomes da Fonseca

Real-world outcomes of chemoimmunotherapy in advanced biliary tract cancer: a multicenter study with a propensity-matched historical cohort

Leonardo Gomes da Fonseca, C. S. Freire, R.A.V. Guedes, M.C. Lyra et autres

Background Biliary tract cancer (BTC) comprises a heterogeneous group of malignancies, often diagnosed at advanced stages. Phase III trials have shown that adding immune checkpoint inhibitors (ICIs) to gemcitabine and cisplatin improves survival, supporting their use as first-line therapy; however, real-world evidence …

br (code pays fourni par la source)

Chronic liver disease is associated with earlier-stage cholangiocarcinoma diagnosis and improved prognosis: Findings from the GLOBAL-BTC registry

Laura Izquierdo-Sanchez, Jone Narbaiza, Julen Martin-Robles, Angela Lamarca et autres

BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is an aggressive cancer with rising incidence and mortality worldwide. Chronic liver disease (CLD) is a well-recognized risk factor, but its influence on tumor presentation and clinical outcomes remains unclear. We aimed to compare the clinical course …

es, gb, nl, in, de, br, no, ar, pe, pl, fr, at, it, us (code pays fourni par la source)

Dose Escalation STRATegy of Regorafenib in Advanced HepatoCellular Carcinoma: Phase II STRATA-HCC Trial

Leonardo Gomes da Fonseca, Murilo Cazellato Pacheco de Mello, Liege Tambellini Gomes, Joao Vitor Antunes Gregorio et autres

All articles of this category (opens in new window) Address for correspondence Leonardo Gomes Da Fonseca (l.fonseca@fm.usp.br) Introduction: Regorafenib prolonged overall survival (OS) after progression on sorafenib in the phase 3 RESOURCE trial with the standard-dose strategy (160 mg/day orally for 21 …

br (code pays fourni par la source)

Predictors of Gastroesophageal Bleeding and Mortality in Patients with Advanced Hepatocellular Carcinoma Under Systemic Therapy

Lucas Takeshi Ikeoka, Leonardo Gomes da Fonseca, Thamires Haick Martins da Silveira, Victor Junji Yamamoto et autres

All articles of this category (opens in new window) Address for correspondence Leonardo Gomes da Fonseca (l.fonseca@fm.usp.br) Introduction: Patients with advanced hepatocellular carcinoma (HCC) often have underlying cirrhosis and portal hypertension, increasing the risk of gastroesophageal varices and upper gastrointestinal bleeding (UGIB). …

br (code pays fourni par la source)

Outcomes of Immunotherapy in Advanced HCC: A Brazilian Multicenter Real-World Study

Cecília Freire, Leonardo Gomes da Fonseca, Marcos Lyra, Rodrigo Guedes et autres

All articles of this category (opens in new window) Address for correspondence Cecília Freire (ceciliasouzafreire@gmail.com) Background: Phase III trials have demonstrated the superiority of immunotherapy-based combinations over sorafenib or lenvatinib in patients with unresectable hepatocellular carcinoma (HCC). However, the adoption of immunotherapy …

br (code pays fourni par la source)

Gastrointestinal bleeding in hepatocellular carcinoma under systemic therapy: Real-world incidence and clinical predictors

Leonardo Gomes da Fonseca, Lucas Takeshi Ikeoka, E. Kim Sampaio, Thamires Haick Martins da Silveira et autres

OBJECTIVE: Gastrointestinal (GI) bleeding is a major complication in patients with advanced Hepatocellular Carcinoma (HCC), particularly among those with underlying portal hypertension. Although systemic therapy has improved survival outcomes, real-world data regarding the incidence, predictors, and clinical impact of GI bleeding remain …

br (code pays fourni par la source)

Cholangiocarcinoma 2026: status quo, unmet needs and priorities

Jesús M. Bañales, Pedro M. Rodrigues, Silvia Affò, Jesper B. Andersen et autres

es, dk, gb, de, it, fr, us, no, ch, nl, ca, gt, ee, th, in, au, ro, ar, se, mx, be, pe, pt, cl, lt, pl, br, gr (code pays fourni par la source)

Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma: BAVENO VII Criteria Still Needs to Be Updated

Federico Piñero, Margarita Anders, Leonardo Gomes da Fonseca, Manuel Mendizábal

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ar, br (code pays fourni par la source)

Fibrolamellar hepatocellular carcinoma: Advances, challenges and opportunities in a rare malignancy

Leonardo Gomes da Fonseca, Raphael L. C. Araújo

Fibrolamellar hepatocellular carcinoma is a rare and unique subtype of primary liver cancer that predominantly affects adolescents and young adults who do not have underlying liver disease or cirrhosis. Representing less than five percent of all liver tumors, it poses significant diagnostic …

br, us (code pays fourni par la source)

Prognostic value of a simplified score based on routine parameters in patients with hepatocellular carcinoma treated with systemic therapies: a retrospective cohort study

Leonardo Gomes da Fonseca, Thamires Haick Martins da Silveira, Victor Junji Yamamoto, Marina Acevedo Zarzar de Melo et autres

Background: The systemic treatment landscape for advanced hepatocellular carcinoma (HCC) has evolved from tyrosine kinase inhibitors, such as sorafenib (SOR), to immune checkpoint inhibitor-based combinations (IO). Despite these advances, there is a lack of simple, objective tools to stratify patient prognosis in …

br (code pays fourni par la source)

CHOLANGIOCARCINOMA IN INDIVIDUALS WITH CHRONIC LIVER DISEASE IS DIAGNOSED EARLIER, LEADING TO BETTER PROGNOSIS

Ángela Lamarca, Heinz‐Josef Klümpen, Arun Valsan, Stéphanie Roessler et autres

Cholangiocarcinoma (CCA) incidence and mortality are rising globally. Chronic liver diseases (CLD) are recognized risk factors. This study aimed to compare the clinical presentation and outcomes of CCA in patients with and without CLD, using data from the International CCA Registry. The …

es, gb, nl, in, de, br, no, ar, pe, pl, us, at (code pays fourni par la source)

1486P Nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib (LEN/SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Efficacy in patients (pts) with poor prognosis and hepatic safety in the overall population from CheckMate 9DW

Thomas Decaens, B. Sangro, Peter R. Galle, Shouming Qin et autres

fr, es, de, cn, br, us, kr, nz, at, sg, it, cl, ro, se, hk (code pays fourni par la source)